latest news releases from the newsroom
Integrity Media: Marks of Progress
LAS VEGAS, March 30, 2009 (GLOBE NEWSWIRE) -- In evaluating small and microcap companies, a critical element is always the depth and acumen of management. In theory, when a company lands a superior talent within its industry amid a chorus of competitive choices, it should say something about the quality of the company which the expert has joined and lent his name. Clearly, there is also the inherent benefit of the new executive's core skill set, relationships, knowledge base, etc. This is perhaps exemplified by the addition of former Burger King senior exec Mark Giresi to the Board of Directors of NXT Nutritionals Holdings, Inc. (OTCBB:NXTH), a developer and marketer of proprietary, patent-pending healthy natural sweeteners, food and beverage products.
Infinity Pharmaceuticals, Inc.
Infinity Initiates International Phase 2 Trial of IPI-504 in Combination With Herceptin(r) in Patients With HER2-Positive Breast Cancer
CAMBRIDGE, Mass., March 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the initiation of a Phase 2 clinical trial of IPI-504 (retaspimycin hydrochloride), its lead heat shock protein 90 (Hsp90) inhibitor, in combination with Herceptin(r) (trastuzumab) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. IPI-504 has demonstrated the potential to disrupt the activity of multiple proteins and cell signaling pathways implicated in tumor growth, including HER2, a key signaling pathway in breast cancer.